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Summary Serum 2-microglobulin (/32-m) is frequently increased in patients with myelomatosis. The
possibility that it could provide a biochemical indicator of prognosis was tested in a group of 129 patients from
3 centres, all serum analyses being carried out in one laboratory by radioimmunoassay. A strong association
between the pretreatment serum ,B2-m level and survival was demonstrated, the data for the 2 main sub-
groups being very similar. In further detailed analyses of 64 patients, serum /2-m proved to be a stronger
indicator of prognosis than current "standard" clinical and laboratory data, including stage determined by the
method of Durie and Salmon and the combination of haemoglobin level and blood urea. The association
between serum /B2-m and survival remained close after treatment as indicated by the findings at one year. The
serum ,B2-m in myeloma reflects the tumour mass and also reduced glomerular filtration when renal failure
supervenes. It is concluded that the serum #2-m is a powerful prognostic indicator in myelomatosis and of
considerable value in the investigation of patients with the disease.
Beta2-microglobulin (, 2-m) forms the light chain
moiety of HL-A (loci A, B, C). Cell membrane
turnover is the principal source of free #2-m in
blood plasma and body fluids (Cresswell et al.,
1974). The serum level is raised in a variety of
malignancies and appears to be a reflection of
tumour load in many patients with lymphomas and
myelomatosis, (Amlot et al., 1978; Child et al., 1980;
Cooper et al., 1981; Bataille et al., 1981; Norfolk et
al., 1980), though its exact cellular origin is as yet
uncertain.
It has been suggested that serum ,B2-m may be of
value as a prognostic indicator in myelomatosis
(Norfolk et al., 1980). Sixty-four patients with this
disease presenting to two centres were therefore
investigated in order to compare the prognostic
information provided by this single protein
measurement with that obtained from existing
staging systems, other clinical features and
"standard" laboratory measurements. To confirm
the results relating survival to serum #2-m an
additional group of 65 patients from a third centre
were investigated.
Patients and methods
All new patients diagnosed as having myelomatosis
at Leeds General Infirmary between January 1975
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and April 1981 (48 patients) and at Bradford Royal
Infirmary between November 1979 and April 1981
(16 patients), who fulfilled the accepted diagnostic
criteria for myelomatosis (Chronic Leukaemia-
Myeloma Task Force, 1973) were included in the
analyses. These 64 patients are referred to as Group
A. A complementary study was made using data on
65 patients with myelomatosis under the care of the
Department of Medical Oncology, Christie Hospital
and Holt Radium Institute, Manchester, who
presented between August 1974 and December
1979. These patients are referred to as Group B.
The stage and renal grade for each patient were
determined according to the system of Durie and
Salmon (1975); the distribution within the 2 main
sub-groups is shown in Table I. The Phadebas /2-
Micro test (Pharmacia, Uppsala, Sweden) was used
to measure serum ,B2-m, which rises slightly with
age but in normal people it rarely exceeds 3mgl- 1.
This level has been taken as the upper limit of
normal appropriate for the age of patients studied.
Measurements were made before treatment was
started and at 3, 6 and 12 months from diagnosis.
All serum #2-m measurements were carried out in
one laboratory (Unit for Cancer Research,
University of Leeds). The details of treatment
are not relevant but most patients were treated
with various combinations of melphalan,
cyclophosphamide and prednisolone.
Statistical methods:
A multivariate regression model (Cox, 1972) was
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Table I Distribution of patients according to serum
/2-m levels, stage* and renal grade*
Group A Group B
Stage and (Leeds & Bradford) (Manchester)
renal grade Serum /2-m mg1` Serum /2-m mg 1
,<4.0 4.1-10.0 >10.0 <,4.0 4.1-10.0 >10.0
IA 15 0 0 5 0 0
IB 0 0 0 0 0 0
IIA 14 5 1 11 7 1
IIB 0 0 1 0 0 2
IIIA 3 7 6 7 16 5
IIIB 2 3 7 0 1 10
*System of Durie & Salmon (1975).
used to assess how different factors related to
patient survival. This model can be used to indicate
the additional prognostic value of a given factor
after allowance has been made for others. Survival
curves using this model were calculated using the
methods suggested by Breslow (1974). The
calculations needed to obtain confidence bands
were those given by Tsiatis (1981) and O'Quigley
(1982). The log rank methods of Peto et al. (1977)
are appropriate when dealing with discrete
prognostic terms; in the present study, however,
continuous measurements of /32-m were used
because it was felt that information would be lost
by using an arbitrary cut-off level as in an earlier
study (Norfolk et al., 1980). A regression model
makes it possible to use the continuous
measurements, though more caution is required,
particularly when plotting the survivorship function.
Even when it is approximately true that survival
varies continuously with a covariate it is likely that
some transformation may be necessary for the
model to be appropriate (in this case it proved
helpful to log the ,B2-m measurements). Assuming
the model to be reasonable, 2 curves can be
obtained corresponding to the 15th and 85th
percentiles and this may give a visual impression as
to the strength of association between ,B2-m and
survival. On average, 15% will do better than
estimated by the upper curve, and 15% will do
worse than estimated by the lower curve, the
remaining 70% lying between the two. From this
model it is possible to obtain the survival curve for
any serum f2-m value. In the case of time-
dependent measurements such as serial
measurements off32-m, the same model can be used
as explained by Kalbfleisch & Prentice (1980)
although survival curves are not then generally
available.
Results
The distribution ofpatients according to serum /32-m
levels (in 3 bands because of the relatively small
numbers per stage) for each stage and renal grade is
presented in Table I. A tendency for serum /2-m to
increase with stage is seen, all 20 patients with stage
I disease having serum ,B2-m levels <4.0mg 1 1 and
55 of 67 patients with stage III disease having
serum ,B2-m levels >4mg1I.
Serum #2-m vs. survival:
The levels of serum ,B2-m at first presentation and
the median survival of subsets, designated by the
initial ,B2-m are shown in Table II. There was a
close similarity in the pattern of results for the 2
patient groups. The remainder of the analyses refer
to Group A patients.
Table II Median survival in relation to pre-
treatment serum /32-m levels
Serum P-m
mgl-l <3.0 3.1-6.0 6.1-10.0 >10.0
Group A
(64 patients) 25 16 8 15
Median survival
(months) 50 22 18 11
Group B
(65 patients) 14 26 7 18
Median survival
(months) 35 24 16 11
The probability of survival given the initial value
of serum ,B2-m as calculated from Cox's regression
model is shown in Table III. The figure shows the
estimated survival of patients with "high"
(12.0mg1-F) and "low" (2.5mgl1) #2-m levels at
diagnosis with the 95% confidence bands.
Comparison between serum /32-m and standard data:
The relationship between the pre-treatment serum
/B2-m and survival was compared with standard
clinical and laboratory data obtained at
presentation. The significance levels of these
associations are presented in Table IV which shows
that the serum 12-m level had the strongest
relationship with survival. Once allowance for 12-m
had been made, the standard data (sex, light chain
class, age, stage, stage and renal grade, blood urea,
haemoglobin level) contributed no further
prognostic information (i.e. statistically non-
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Table III Probability of surviving (95% confidence limits) given the initial
value of serum ,B2-m as calculated from Cox's regression model
Initial value ofserum ,B2-m mg 1
Survival time 2.0 4.5 8.0 15.0
5 months 0.95 0.89 0.82 0.68
(0.98,0.88) (0.95,0.80) (0.90,0.68) (0.82,0.47)
12 ,, 0.91 0.80 0.68 0.48
(0.96,0.81) (0.88,0.68) (0.79,0.52) (0.66,0.26)
18 ,, 0.80 0.60 0.40 0.17
(0.89,0.65) (0.72,0.45) (0.55,0.24) (0.36,0.05)
24 ,, 0.71 0.46 0.24 0.07
(0.83,0.53) (0.60,0.30) (0.39,0.12) (0.12,0.01)
38 ,, 0.64 0.36 0.16 0.03
(0.78,0.44) (0.52,0.20) (0.32,0.02) (0.15,0.001)
60 ,, 0.40 0.12 0.02 0.0
(0.65,0.14) (0.35,0.01) (0.17,0.003) (0.05,0.0)
0 12 24 36 48 S
SurM ime timointh.
Figure 1 Estimated survival of patients with "high"
(12.Omgl-') and "low" (2.5mgl-') serum ,B2-m levels
at diagnosis, with 95% confidence bands.
model after accounting for the standard data is
shown in Table V. Haemoglobin and blood urea
were both, as expected, indicators of prognosis but
they were not individually or together as powerful
as serum /32-m; the addition of serum /32-m to the
model gave a significant result even after
haemoglobin and blood urea had been taken into
account. Similarly, clinical stage and survival
showed a relationship which was significantly
enhanced by the addition of serum #32-m (Table V).
By including the serial measurement of serum /32-m
made at 3, 6 and 12 months after diagnosis as well
as the initial measurement, a highly significant
result was obtained (P<0.001) but only slightly
more powerful than that using the initial
Table IV Relationship
clinical features/laboratory
ments at presentation and
between
measure-
survival.
p
Sex NS
Light chain class NS
Age <0.05
Stage* <0.001
Stage* and renal grade* <0.001
Blood urea <0.005
Haemoglobin level <0.001
Serum 32-m «0.001
NS=Not significant.
*System of Durie & Salmon (1975).
measurement alone. The measurements of serum
#2-m alone, at 12 months from diagnosis, in Cox's
model carried significant prognostic information
(P<0.005).
Discussion
The staging of myelomatosis has, in recent years,
been dominated by the system of Durie and Salmon
(1975) which has been shown to give a good
correlation between stage and survival (Woodruff et
al., 1979) but which has been criticised because it
allocates a high proportion of cases to Stage III114 J.A. CHILD et al.
Table V Significance of including serum /32-m after
clinical features/laboratory measurements have been
accounted for.
p
Age+serum /B2-m <0.001
Stage* +serum /32-m <0.001
Stage* and renal grade* +serum /32-m <0.001
Blood urea+serum /32-m <0.001
Haemoglobin+serum /32-m <0.005
Blood urea+haemoglobin+serum /32-m <0.01
*System of Durie & Salmon (1975).
(Parker & Malpas, 1979). The Medical Research
Council group found that the blood urea and the
haemoglobin level were the most significant
parameters in assessing the prognosis of myeloma
patients and together with performance status they
form the basis of the system of staging which they
adopted. (Medical Research Council, 1980).
The results of the present study have shown that
serum 42-m measured at presentation has a strong
association with survival, the data for 2 comparable
groups of patients being very similar. The
additional analyses revealed that the serum /2-m
was a better guide to prognosis than the other
"standard" clinical and laboratory data, whether
derived from the combination of haemoglobin level
and blood urea or stage based on the system of
Durie & Salmon (1975).
The haemoglobin level is likely to be related to
marrow involvement and therefore, tumour load,
whilst blood urea reflects the renal effects of
myelomatosis, probably light chain excretion. The
level of P2-m in serum, reflecting myeloma cell mass
but also rising as the glomerular filtration rate falls,
represents the net effect of tumour mass together
with a contribution from reduced filtration in
patients with impaired renal function. The serum
32-m continues to give powerful prognostic
information after the institution of treatment as
demonstrated by the findings at one year. This
reinforces earlier observations that the prognosis for
patients whose serum /32-m levels fall and stabilise
at normal or near normal levels after treatment is
better than for patients with persistently high or
rising levels (Norfolk et al., 1980).
It is concluded that the serum ,B2-m at diagnosis
carries more prognostic information than any of the
commonly used indicators in myelomatosis and
should, therefore, have a valuable role in the
investigation of patients with this disease and their
stratification for clinical trial purposes. The use of a
single simple measurement has obvious attractions.
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